to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Pulse pressure and coronary atherosclerosis progression in postmenopausal women.
Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease.
Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease.
Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women.
Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned.
Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).
Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial.
Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women.
The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial.
Progestins affect mechanism of estrogen-induced C-reactive protein stimulation.
Effects of conjugated equine estrogen on stroke in the Women's Health Initiative.
Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative.
Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women.
Submaximal exercise coronary artery flow increases in postmenopausal women without coronary artery disease after estrogen and atorvastatin.
Estrogens, Conjugated (USP)